Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor

Abstract

Background/Aim: The present research was performed to clarify the differences in circulating tumor cells (CTCs) counts between non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer following transurethral resection of bladder tumor (TURBT). Patients and Methods: The cohort in the prospective research was categorized into the NMIBC (n=13) and the MIBC (n=13) groups. The pre-and postoperative number of CTCs was counted by the FISHMAN-R ® system. Results: The difference of the number of preoperative CTCs between the NMIBC group (2.3±2.6) and MIBC group (4.8±4.2) did not reach statistical significance (p=0.08). However, there was a significantly greater increase in postoperative CTC count in the MIBC group (14.6±14.6) than in the NMIBC group (3.1±2.1, p=0.01). Conclusion: After TURBT, more carcinoma cells can be discharged from the bladder in the MIBC. Excessive deep layer resection and excessive pressure of the infusion fluid during TURBT should be avoided in patients with MIBC. Patients and MethodsPatient cohort and design of the study. This single-center, prospective cohort study included the patients for whom TURBT were performed at a university hospital between December 2018 and September 2019. The study protocol was approved by the institutional review board 4299

Evaluation of Sleep Disturbances in Patients With Bladder Cancer Scheduled for Local or Loco-regional Radiochemotherapy

“…Many patients with cancer of the urinary bladder receive local or loco-regional radiotherapy with or without concurrent chemotherapy as part of a bladder-preserving multimodal treatment (12)(13)(14)(15)(16)(17). Anticipation of radiochemotherapy or radiotherapy can be associated with sleep disturbances as a consequence of emotional distress and fears.…”

The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer

“…The presence of CTCs predicting decreased time to first recurrence and time to progression identified a subgroup of patients with super-high-risk CTC-positive NMIBC. There was a non-statistical difference in the number of preoperative CTCs between the NMIBC and MIBC patients, suggesting that further investigation is needed [26].…”

“…Regarding BC, in a cohort of T1 BC patients, the presence of CTCs correlated with a shorter time to first recurrence and time to progression [24,25]. Nevertheless, there was a non-statistical difference in the number of preoperative CTCs between the NMIBC and MIBC patients, suggesting that further analysis is needed [26]. Since the isolation of CTCs suggests that invasive treatment gives rise to the possibility of spreading into the systemic circulation [27][28][29], the discovery of diagnostic and prognostic molecular information from CTCs is critical [30].…”

Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review

“…First, in several studies, some of the patients (ranging from 6.1% to 12.8%) were staged as pT0, indicating that the CTC detection rate would have been higher had the analysis been focused on patients staged pT1 or greater [ 23 , 24 , 25 ]. Second (and in contrast), the detection rate might have been lower had the blood sampling been performed before transurethral resection of the BCa, because transurethral resection of aggressive BCa can lead to dissemination of CTCs; a rise in CTC count after surgery was found in 52.9% (9/17) of MIBC cases and in 30.8% (4/13) of cases of high-grade disease [ 26 , 27 ]. Third, the most fundamental concern is that the detection power of the molecular approach is limited by its sole focus on EpCAM.…”